The purpose of this study to develop an international tool that can be used to assess burden of disease in patients enrolled in the W\&W program for rectal cancer
The watch-and-wait (W\&W) strategy in rectal cancer is a organ-sparing treatment option, where patients with a clinical complete response (cCR) after neoadjuvant chemo(radio)therapy, do not undergo surgery but instead follow a strict follow-up scheme. The goal of the W\&W strategy is to preserve the rectum and thereby retain functional outcomes (FO) (e.g. gastro-intestinal, urinary, sexual) and improve quality of life (QoL). Patient Reported Outcome Measures (PROMs) reflect the patients' evaluation of their symptoms, FO and QoL. In the W\&W program various PROMs (e.g. EORTC-CR29/C30, LARS, SF-36) are used to assess the these different outcomes. However, most of the PROMs used are developed and validated in a surgical patient group. So the relevance and usefulness of these PROMs may be limited in W\&W patients. For use in clinical practice, a short PROM would support follow-up care as it provides a clear overview of the problems W\&W patients experience. This paper describes the protocol for the development of an international tool that can be used to assess burden of disease in patients enrolled in the W\&W program for rectal cancer. We will use the Delphi methodology to reach consensus about items that should be included in the novel tool. The aim of this tool is to improve direct patient care during the entire Watch-and-Wait program.
Study Type
OBSERVATIONAL
Enrollment
80
During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W\&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item. After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached.
Maastricht UMC
Maastricht, Limburg, Netherlands
Consensus in / Important outcome
\>70% of the participants in each panel rating the outcome '7-9' OR \<70% of the clinicians and (clinical) researchers rating the outcome '7-9' but an average patient rating of \>7
Time frame: between 3 months and 5 years of follow up
Consensus in / No important outcome
\<70% of the clinicians and (clinical) researchers rating the outcome '7-9' AND an average patient rating of \<7
Time frame: between 3 months and 5 years of follow up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.